Qixin New Era Unveils Enterprise AI Strategy for Medical Aesthetics at YinYuan Galaxy Online Salon, Files IPO Prospectus

On December 31, 2025, the online industry salon titled “When AI Becomes the Enterprise Brain,” hosted by Yin Yuan Xinghe, was successfully held. Wang Yue, CEO of Qi Xin Ji Yuan, was invited to attend the event and joined guests from various fields in discussing innovative applications and future development of enterprise-grade AI. During the discussion session, Wang Yue focused on the unique characteristics of the healthcare sector, providing an in-depth analysis of the transformation and value brought by enterprise-grade AI. He explicitly stated that Qi Xin Ji Yuan would continue to intensify its efforts to promote the large-scale implementation and deep application of advanced AI technologies across the entire medical aesthetics industry chain, thereby injecting intelligent momentum into the industry’s development.

During the roundtable discussion, participants reached an important consensus: as a typically high-complexity sector, the healthcare industry is characterized by lengthy value chains, diverse stakeholders, and stringent regulatory compliance. Moreover, the prevalence of data silos and fragmented system architectures poses significant challenges to enterprise operations and collaboration.

Addressing this industry pain point, attendees at the event pointed out that in the highly regulated and strictly constrained environment of the healthcare sector, if AI technology remains limited to isolated, point-specific applications, it will fail to meet the needs of cross-departmental collaboration or support the long-term, stable operations of enterprises. What companies truly need is to build “centralized AI capabilities”—that is, to deeply embed AI technology into the entire business workflow under a clear system of rules and governance framework. Through continuous iteration and optimization, this approach achieves deep integration of technology and business, providing sustained support for corporate development.

In terms of the practical implementation of AI in the healthcare industry, participating guests engaged in in-depth discussions around typical industry challenges, directly addressing pain points and pathways to breakthroughs. The guests pointed out that reaching doctors with academic information and content has long faced industry-wide difficulties such as low efficiency and high maintenance costs. Especially in the absence of standardized governance over content systems, it is not only difficult to ensure the compliance and consistency of information output but also may bring potential risks to corporate operations. The application of AI technology can precisely force enterprises to systematically organize and reconstruct their internal content, knowledge reserves, and business processes, making "compliance and controllability" truly the core foundation for the sustainable operation of healthcare companies.

The medical aesthetics industry, characterized by its long value chain and high demand for cross-departmental collaboration, has an urgent need for “AI-centric capabilities.” By integrating key data from various nodes to drive decision-making, AI-centric capabilities can precisely address pain points across the entire industry chain—including medical compliance, personalized service delivery, marketing and customer acquisition, and operational management. This helps medical aesthetics institutions break free from homogeneous competition and build core competitive barriers. Furthermore, in light of the industry’s structure—marked by high technological barriers upstream, fragmented competition in the midstream, and diversified channels downstream—AI-centric capabilities enable end-to-end data interoperability and collaboration, significantly enhancing the overall efficiency and value creation capacity of the medical aesthetics industry chain.

Wang Yue, CEO of Qixin Jiyuan, stated that AI applications must effectively address industry-specific challenges, and that the “Enterprise AI Decision-Making and Action Hub” can be further implemented within the new ecosystem of smart medical aesthetics. Leveraging its parent company’s robust computing power, technical development capabilities, diversified ecosystem businesses, and in-depth strategic planning in the healthcare sector, Qixin Jiyuan is strategically positioning itself across the entire medical aesthetics industry chain. The company will gradually enhance its proprietary capabilities in medical aesthetic products, equipment, physicians, and institutions. In the future, it will deeply cultivate multiple independent brands and IPs in the medical aesthetics sector, progressively establishing an integrated layout with autonomous capabilities in research, development, production, and sales.

During discussions on global expansion, panelists clarified the two-phase impact of AI on enterprises: in the early stage, AI optimizes existing business processes through automation and intelligentization, achieving cost reduction and efficiency gains; as technological capabilities mature, AI will profoundly reshape organizational collaboration models and business operational mechanisms, driving enterprises to transition from “tool users” to an advanced form of “AI-driven operations.”

Wang Yue stated that Qixin Jiyuan will gradually expand its medical aesthetics products and services in both domestic and international markets, establishing an overseas brand image characterized by the integration of high-end products and equipment with top-tier medical aesthetics physicians. What medical aesthetics companies truly lack is not more AI tools, but rather the systemic capability to transform AI into deliverable, quantifiable, and replicable solutions. By deeply integrating its AI technological advantages and empowering operations through intelligence, Qixin Jiyuan aims to enhance its brand’s global competitiveness and support the globalization of its medical aesthetics business.